Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Salvianolic Acid A in Healthy Volunteers
NCT03791125Phase 1Unknown
- Sponsor
- Peking University First Hospital
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of salvianolic acid a in diabetic neuropathy (2 arms), sponsored by Peking University First Hospital. Primary endpoints: Subject incidence of treatment-emergent adverse events at 7 days, Percentage of participants with change from baseline in vital signs at 7 days and 5 more. Status: unknown.
02
Drugs
salvianolic acid a
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT03791125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03791125.